Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.
Adjuvants, Immunologic
/ administration & dosage
Age Factors
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Cost-Benefit Analysis
Humans
Influenza Vaccines
/ economics
Influenza, Human
/ prevention & control
Polysorbates
/ administration & dosage
Risk Factors
Squalene
/ administration & dosage
Vaccination
/ economics
Influenza
MF59
adjuvated
economic evidence
older age
systematic review
trivalent
vaccine
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
9
2
2019
medline:
29
2
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure. It is, however, unclear which available alternative has the most favorable economic profile. Some available options are: trivalent (TIV) and quadrivalent (QIV) inactivated vaccines, adjuvanted TIV (aTIV). Because of immunosenescence, aTIV has been specifically developed for elderly. The present study aimed at assessing the available evidence of aTIV use in elderly from the economic perspective. A systematic literature review targeting aTIV economic evaluations in adults aged ≥65 years was performed using Medline via Ovid, Embase, DARE and NHS/EED. Of a total of 3,654 papers screened, 18 studies (13 full papers, 5 conference abstracts) were included. It emerged that compared with both non-vaccination or non-adjuvanted vaccines, aTIV was cost-effective or cost-saving. The vaccinations strategies incorporating aTIV based on age and/or risk profile are associated with the most favorable economic outcomes.
Identifiants
pubmed: 30735465
doi: 10.1080/21645515.2019.1578597
pmc: PMC6605847
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Viral
0
Influenza Vaccines
0
MF59 oil emulsion
0
Polysorbates
0
Squalene
7QWM220FJH
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1035-1047Références
Cochrane Database Syst Rev. 2018 Feb 01;2:CD004876
pubmed: 29388197
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
BMJ. 2014 Oct 03;349:g5741
pubmed: 25281681
Ann Ist Super Sanita. 2018 Jan-Mar;54(1):49-57
pubmed: 29616674
Vaccine. 2001 Mar 21;19(17-19):2673-80
pubmed: 11257408
Vaccine. 2017 Apr 4;35(15):1828-1843
pubmed: 28284681
Vaccine. 2010 Feb 25;28(9):2149-56
pubmed: 20003926
Expert Rev Pharmacoecon Outcomes Res. 2006 Jun;6(3):293-301
pubmed: 20528523
MMWR Recomm Rep. 2018 Aug 24;67(3):1-20
pubmed: 30141464
Int J Evid Based Healthc. 2015 Sep;13(3):170-8
pubmed: 26288063
Expert Rev Vaccines. 2011 Apr;10(4):447-62
pubmed: 21506643
Hum Vaccin Immunother. 2018 Jun 3;14(6):1331-1341
pubmed: 29425079
J Prev Med Hyg. 2011 Mar;52(1):1-8
pubmed: 21710816
Clin Infect Dis. 2019 May 2;68(10):1754-1757
pubmed: 30312364
PLoS One. 2011;6(11):e27420
pubmed: 22110645
Value Health. 2013 Mar-Apr;16(2):e1-5
pubmed: 23538200
J Infect Dis. 2019 Sep 13;220(8):1255-1264
pubmed: 30561688
Vaccine. 2017 Jan 23;35(4):513-520
pubmed: 28024956
Expert Rev Vaccines. 2018 May;17(5):435-443
pubmed: 29715054
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Expert Rev Vaccines. 2016 Dec;15(12):1495-1505
pubmed: 27813430
PLoS One. 2017 Apr 25;12(4):e0176210
pubmed: 28441452
Rev Esp Quimioter. 2018 Feb;31(1):43-52
pubmed: 29355006
Vaccine. 2017 Jul 24;35(33):4167-4176
pubmed: 28655451
Vaccine. 2009 Apr 6;27(16):2251-7
pubmed: 19428839
Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249-265
pubmed: 28613092
J Prev Med Hyg. 2017 Dec 30;58(4):E279-E287
pubmed: 29707658
Pharmacoeconomics. 2017 Nov;35(11):1123-1140
pubmed: 28875314
Vaccine. 2013 Dec 5;31(50):6030-3
pubmed: 24095882
J Am Geriatr Soc. 2016 Oct;64(10):2126-2131
pubmed: 27709600
BMJ Open. 2017 Jun 10;7(6):e014847
pubmed: 28601824
Influenza Other Respir Viruses. 2018 Jul;12(4):533-543
pubmed: 29498477
Hum Vaccin. 2010 Oct;6(10):841-8
pubmed: 20930559
Influenza Other Respir Viruses. 2018 Mar;12(2):211-219
pubmed: 29024434
Hum Vaccin Immunother. 2018 Mar 4;14(3):699-705
pubmed: 29059004
Expert Rev Vaccines. 2013 Sep;12(9):1085-94
pubmed: 24024871
N Engl J Med. 2016 Sep 29;375(13):1261-8
pubmed: 27682035
Euro Surveill. 2018 Apr;23(16):
pubmed: 29692315
Hum Vaccin Immunother. 2016 Oct 2;12(10):2616-2627
pubmed: 27246556
JAMA. 2003 Jan 8;289(2):179-86
pubmed: 12517228
Br J Gen Pract. 2016 Sep;66(650):452-3
pubmed: 27563114
Gerontology. 2003 May-Jun;49(3):177-84
pubmed: 12679609
Infect Dis Ther. 2015 Dec;4(4):459-87
pubmed: 26350238